| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d424501f2cc71f68093d9721941954d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37b416a8c0d2b0f1c3d6026d932027af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c87b1f7158bec499783fa1b27aad08c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2029c6d29925327149e40809dc29b7ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18d3abf9438d7f8307507c899fe2f6ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_701b0916e480656e70659f3a988486db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac49f320e5bc50ddb200f304eb61d1d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc5a9d330cba04cc10c5e0c85596570a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cff68a2088508819e4749ab8226467e |
| publicationDate |
2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210148077-A |
| titleOfInvention |
How to Predict Benefit from Immune Checkpoint Suppression Therapy |
| abstract |
The present invention provides a method for identifying a patient suffering from cancer as either benefiting or not receiving an immune checkpoint suppression therapy, wherein the expression level of one or more preselected markers in a cancerous biological sample obtained from the patient measuring; identifying alternative promoters that are differentially expressed based on the expression level of one or more preselected markers; calculating an alternative promoter usage score (APB score); and using the APB score to identify the patient as benefiting or not benefiting from an immune checkpoint suppression therapy. In particular, patients with high APB scores have lower expression of CD8A, granzyme A and perforin I, and have worse progression-free survival than patients with low APB scores. Patients with lower APB scores have higher objective response rates compared to patients with APB scores. |
| priorityDate |
2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |